Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01635712 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
A Phase 1 study, sponsored by Esanex.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01635712 is a Phase 1 study that has completed, run by Esanex. The registered enrollment target is 10 participants.
The verdict
NCT01635712, a Phase 1 study, has completed, sponsored by Esanex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Hsp90 is a chemical in the body that is involved int he promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90.
Interventions
- DRUG SNX-5422
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-02 |
| Est. Completion | 2017-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01635712
The ClinicalTrials.gov registry entry for NCT01635712 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Esanex, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SNX-5422 is the first listed.
NCT01635712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01635712 about?
NCT01635712 is a clinical study titled "Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies". Hsp90 is a chemical in the body that is involved int he promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90.
What is the current status of trial NCT01635712?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2014-02. Estimated completion is 2017-02.
What interventions are being tested in trial NCT01635712?
The interventions under investigation include: SNX-5422 (DRUG).
Who is sponsoring clinical trial NCT01635712?
This trial is sponsored by Esanex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.